article thumbnail

Apoptosis Regulator BAX drugs in development, 2023

Pharmaceutical Technology

GlobalData’s report assesses the drugs in the Apoptosis Regulator BAX pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

article thumbnail

Apoptosis Regulator BAX drugs in development, 2023

Pharmaceutical Technology

GlobalData’s report assesses the drugs in the Apoptosis Regulator BAX pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Interview: Is global AI regulation really revolutionizing pharma and clinical trials?

Outsourcing Pharma

OSP spoke to Berkeley Research Group healthcare managing director, Wendy Cheng for a discussion around developments in AI regulation for pharmaceuticals, clinical trials, and drug development at a global scale.

article thumbnail

Selective Translation Regulator Inhibitors: Depriving cancer of what it needs

Drug Discovery World

Each of these targets regulates distinct sets of genes in cancer and immune cells. The post Selective Translation Regulator Inhibitors: Depriving cancer of what it needs appeared first on Drug Discovery World (DDW). In this episode, Megan Thomas is in conversation with Steve Worland, CEO of eFFECTOR.

article thumbnail

The opportunities and challenges facing rare disease therapies developers

pharmaphorum

Explore the opportunities and challenges facing rare disease therapies developers, including the impact of Rare Disease Day, FDA regulations, and cutting-edge technologies like CRISPR gene therapy.

article thumbnail

Biotech execs say IRA is causing unintended effects for cancer drug development

Pharmaceutical Technology

IRA regulations have changed how pharma is approaching innovation in cancer drug discovery and development.

article thumbnail

MHRA revamps UK clinical trial regulation with the promise of faster timelines

Pharmaceutical Technology

This week, the Medicines and Healthcare products Regulatory Agency (MHRA) is introducing major changes to clinical trial regulation in the UK with expedited timelines at several stages. The MHRA hopes this new framework “will remove obstacles to innovation” and “streamline the regulation of clinical trials” amongst other things.